Home
Commercial Solutions
Back
Integrated Commercial Services
Back
Advisory Services
Back
Management Consulting
Regulatory Consulting
Specialty Consulting
Canadian Advisory Services
HEOR, Value & Evidence
Patient Services
Back
Access & Hub
Adherence Solutions
Affordability, Co-Pay & PAP
Specialty Pharmacy
In-Home Nursing & Clinical Support
Clinical Trial Programs
Field Deployment Solutions
Back
Field Deployment Solutions
Medical Deployment Solutions
Learning & Performance Services
Market Access
Back
Market Access Strategies
Market Shaping Activation Model
Market Access & Reimbursement
Market Research & Insights
RWE & HEOR
Pricing & Revenue Management
Back
Global Pricing & Access
Market Access & Reimbursement
Revenue Management
Research & Insights
Medical Affairs
Back
Medical Affairs Strategy
Integrated Compliance Solutions
Medical Information
Pharmacovigilance
Quality Assurance/Quality Management Systems
Regulatory
Medical Affairs Technology Innovation
Agency Solutions
Back
Patient, Payer & Provider Marketing Agency
Digital Transformation & Innovation
Omnichannel Platform
Trade, Channel & 3PL
Back
Global Channel Management & 3PL
e-Commerce
Data & Analytics
Back
Data & Analytics Solutions
Analytics as a Service
Advanced Analytics
Field Force Optimization Strategies
Integrated Commercial Models
Back
EVERSANA COMPLETE Commercialization®
EVERSANA DIRECT Commercialization™
EVERSANA ONCOLOGY Commercialization®
EVERSANA REIGNITE™
Technology & Innovation
Back
EVERSANA ORCHESTRATE
Back
EVERSANA ORCHESTRATE MLR
EVERSANA ORCHESTRATE Omnichannel
NAVLIN Pricing & Market Access
Back
Global Pricing & Access Data
Research & Insights
Revenue Management
Price & Access Software
ACTICS Infrastructure & Data
Back
ACTICS Patient Relationship Management
ACTICS eAccess
Chronic Disease RWD
Solve Commercial Challenges
Back
Assess Commercial Readiness in Europe
Market Shaping Activation Model
Propel Commercialization with D&A
Reach Patients & Sustain Adherence
Penetrate & Expand Markets
Optimize Product Launch
Ensure Market Access
Maintain Safe & Effective Usage
Mobilize High Performing Sales Force
Distribute in Effective & Efficient Ways
Optimize Pricing & Reimbursement
Achieve Stakeholder Intimacy
Value Across Life Cycle
Back
EVERSANA COMPLETE Commercialization®
EVERSANA’s Direct-to-Patient Care Model
Launch Readiness
Product Launch
In Market
Established Brands
Therapeutic Expertise
Back
Oncology & Hematology
Neurology & CNS
Rare
Cell & Gene
Digital Medicines
About
Back
Beliefs
Leaders
Experts
Locations
Awards
Events
Insights
Back
Thought Leadership
Scientific Insights
News
Careers
Search
Select a Region
North America
Asia Pacific
Europe
North America
Contact
menu
Home
Commercial Solutions
Integrated Commercial Services
Advisory Services
Management Consulting
Regulatory Consulting
Specialty Consulting
Canadian Advisory Services
HEOR, Value & Evidence
Patient Services
Access & Hub
Adherence Solutions
Affordability, Co-Pay & PAP
Specialty Pharmacy
In-Home Nursing & Clinical Support
Clinical Trial Programs
Field Deployment Solutions
Field Deployment Solutions
Medical Deployment Solutions
Learning & Performance Services
Market Access
Market Access Strategies
Market Shaping Activation Model
Market Access & Reimbursement
Market Research & Insights
RWE & HEOR
Pricing & Revenue Management
Global Pricing & Access
Market Access & Reimbursement
Revenue Management
Research & Insights
Medical Affairs
Medical Affairs Strategy
Integrated Compliance Solutions
Medical Information
Pharmacovigilance
Quality Assurance/Quality Management Systems
Regulatory
Medical Affairs Technology Innovation
Agency Solutions
Patient, Payer & Provider Marketing Agency
Digital Transformation & Innovation
Omnichannel Platform
Trade, Channel & 3PL
Global Channel Management & 3PL
e-Commerce
Data & Analytics
Data & Analytics Solutions
Analytics as a Service
Advanced Analytics
Field Force Optimization Strategies
Integrated Commercial Models
EVERSANA COMPLETE Commercialization®
EVERSANA DIRECT Commercialization™
EVERSANA ONCOLOGY Commercialization®
EVERSANA REIGNITE™
Technology & Innovation
EVERSANA ORCHESTRATE
EVERSANA ORCHESTRATE MLR
EVERSANA ORCHESTRATE Omnichannel
NAVLIN Pricing & Market Access
Global Pricing & Access Data
Research & Insights
Revenue Management
Price & Access Software
ACTICS Infrastructure & Data
ACTICS Patient Relationship Management
ACTICS eAccess
Chronic Disease RWD
Solve Commercial Challenges
Assess Commercial Readiness in Europe
Market Shaping Activation Model
Propel Commercialization with D&A
Reach Patients & Sustain Adherence
Penetrate & Expand Markets
Optimize Product Launch
Ensure Market Access
Maintain Safe & Effective Usage
Mobilize High Performing Sales Force
Distribute in Effective & Efficient Ways
Optimize Pricing & Reimbursement
Achieve Stakeholder Intimacy
Value Across Life Cycle
EVERSANA COMPLETE Commercialization®
EVERSANA’s Direct-to-Patient Care Model
Launch Readiness
Product Launch
In Market
Established Brands
Therapeutic Expertise
Oncology & Hematology
Neurology & CNS
Rare
Cell & Gene
Digital Medicines
About
Beliefs
Leaders
Experts
Locations
Awards
Events
Insights
Thought Leadership
Scientific Insights
News
Careers
Search
Newscenter
Browsing Archive: ArticleArticle | EVERSANA
Posted on
June 12, 2025
6/12/25
Network Meta-Analysis of Pharmacological Therapies for Long-Term Prophylactic Treatment of Patients with Hereditary Angioedema
Posted on
May 8, 2025
5/8/25
Continuous glucose monitoring for self-management of diabetes in people living with type 2 diabetes mellitus on basal insulin therapy: A microsimulation model and cost-effectiveness analysis from a US perspective with relevance to Medicaid
Posted on
May 8, 2025
5/8/25
The economic impact associated with stent retriever selection for the treatment of acute ischemic stroke: a cost–effectiveness analysis of MASTRO I data from a Chinese healthcare system perspective
Posted on
May 8, 2025
5/8/25
A U.S. payer budget impact analysis of Flurpiridaz-PET-MPI compared to SPECT-MPI in the diagnosis of coronary artery disease
Posted on
May 8, 2025
5/8/25
Systematic literature review and meta-analysis of health state utility values in metastatic castration-resistant prostate cancer
Posted on
May 8, 2025
5/8/25
Real-world effectiveness of CDK4/6i in first-line treatment of HR+/HER2− advanced/metastatic breast cancer: updated systematic review
Posted on
April 29, 2025
4/29/25
Efficacy and safety of crizotinib in the treatment of advanced non-small cell lung cancer with ROS1 gene fusion: a systematic literature review and meta-analysis of real-world evidence
Posted on
April 29, 2025
4/29/25
The economic impact associated with stent retriever selection for the treatment of acute ischemic stroke: a cost–effectiveness analysis of MASTRO I data from a Chinese healthcare system perspective
Posted on
April 29, 2025
4/29/25
A U.S. payer budget impact analysis of Flurpiridaz-PET-MPI compared to SPECT-MPI in the diagnosis of coronary artery disease
Posted on
April 29, 2025
4/29/25
Systematic literature review and meta-analysis of health state utility values in metastatic castration-resistant prostate cancer
Page 1 of 18
1
2
3
4
5
...
10
...
»
Last »
Article
